Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Fruquintinib × HMPL-013 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 47 Stomach Neoplasms 11 Colonic Neoplasms 6 Rectal Neoplasms 4 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 NSCLC 2 Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Advanced Solid Tumors 2 Advanced Colorectal Carcinoma 2 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Patients With Advanced Metastatic Colorectal Cancer 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Metastatic Colorectal Adenocarcinoma 1 Metastasis Colorectal Cancer 1 MSS Metastatic Colorectal Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Locally Advanced Rectal Cancer 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡